Brind.

Immuron Reports Mixed North American Revenue for Q1 FY2027

2 reports, 2 independent Updated Nov 4
No new developments lately Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Immuron reported that global product revenue increased 9% year-over-year to AUD $2.2 million for the first quarter of FY2027, which ended September 30, 2026. North American results were mixed: U.S. revenue declined 19% year-over-year because of customs and logistics delays, while Canadian revenue increased 286%. Australia recorded 14% year-over-year revenue growth.

From pr-inside.com, timesargus.com

Why it matters

Some supportBrind's analysis of the reports

The company reported that its FY2026 net loss of AUD $3.8 million was an improvement of $1.4 million from the previous fiscal year. Immuron expects continued sales growth for Travelan® and expansion of its product portfolio and geographic reach.

From pr-inside.com, timesargus.com

Who's involved

  • ImmuronSmall biotech company reporting Q1 FY2027 financial results
  • NasdaqStock exchange where Immuron is publicly listed

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • NasdaqSpeculative

    Immuron's revenue performance could affect its market valuation on Nasdaq.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped